This is a small study out of Denmark that involved 105 prostate cancer patients who were starting on an LHRH agonist, LHRH antagonists, or receiving an orchiectomy. The patients’ median Gleason score was 7, but their PSA levels were fairly high; i.e., mean of 181 ng/ml.
Over two years the prevalence of osteoporosis rose from 10 to 22%. During that same period one in 12 of the patients experienced a fracture, and several of these fractures were reported as serious.
These findings are not new, but they reinforce the conclusion that ADT carries a high risk of osteoporosis and fracture.
To read the study abstract, please see:
Poulsen, M. H., Frost, M., Abrahamsen, B., Gerke, O., Walter, S., & Lund, L. (2019). Osteoporosis and prostate cancer: A 24-month prospective observational study during androgen deprivation therapy. Scandinavian Journal of Urology, 1-6. [Epub ahead of print]. doi: 10.1080/21681805.2019.1570328